CapsoVision, Inc.
CVHealthcareNASDAQMedical Devices · Last scanned Sep 9, 2026
Scan Results
Daily timeframeCapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company carries a $318.3M market cap, placing it firmly in the small-cap category. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Market Cap
$318.3M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-1.11
EPS (Fwd)
—
ROE
-335.1%
ROA
-132.5%
Cash
$9.1M
Total Debt
$687,000
Free CF
-$16.3M
52W Change
65.0%
Annual Financials
Cash vs Debt
Where CV stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CV finished 6.32% below its 150-day moving average ($6.33) and 12.54% below its 200-day moving average ($6.78). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CV overbought or oversold?
At the September 3, 2026 close, CV's RSI(14) was 25.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $9.1M in cash and $687K in debt, CV maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$16.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -335.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $9.8M (2023) to $13.6M (2025), reflecting a 39% increase over the period.
With cash comfortably exceeding debt, CV has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing CV's risk profile alongside its fundamentals and technical indicators provides a more complete picture.